Free tool
FAERS Monitor: Ciloxan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019992 or its brand name (Ciloxan, Ciprofloxacin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
6,204
Serious
5,373
87% of reports
Hospitalization
2,322
Death reported
523
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting752
- pneumonia707
- dyspnoea698
- off label use668
- pain654
- nausea641
- drug hypersensitivity637
- malaise592
- diarrhoea587
- drug ineffective543
- fatigue533
- wheezing522
- headache511
- asthma456
- oedema441
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 67 |
| 2006 | 63 |
| 2007 | 66 |
| 2008 | 89 |
| 2009 | 163 |
| 2010 | 80 |
| 2011 | 119 |
| 2012 | 298 |
| 2013 | 72 |
| 2014 | 81 |
| 2015 | 108 |
| 2016 | 132 |
| 2017 | 141 |
| 2018 | 275 |
| 2019 | 501 |
| 2020 | 417 |
| 2021 | 477 |
| 2022 | 603 |
| 2023 | 612 |
| 2024 | 676 |
| 2025 | 679 |
| 2026 | 441 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,955 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| wheezingSignal | 522 | 30.1 | 27.7 | 14,568 |
| oedemaSignal | 441 | 27.8 | 25.4 | 11,297 |
| asthmaSignal | 456 | 13.7 | 12.6 | 5,377 |
| drug hypersensitivitySignal | 637 | 11.2 | 10.4 | 5,938 |
| pneumoniaSignal | 707 | 7.4 | 6.9 | 3,971 |
| vomitingSignal | 752 | 5.4 | 5.1 | 2,771 |
| malaiseSignal | 592 | 4.6 | 4.2 | 1,687 |
| dyspnoeaSignal | 698 | 4.2 | 3.9 | 1,733 |
| painSignal | 654 | 3.6 | 3.4 | 1,269 |
| diarrhoeaSignal | 587 | 3.1 | 2.9 | 850 |
| headacheSignal | 511 | 2.8 | 2.5 | 591 |
| nauseaSignal | 641 | 2.7 | 2.6 | 738 |
| off label useSignal | 668 | 2.6 | 2.4 | 677 |
| fatigueSignal | 533 | 2.3 | 2.1 | 415 |
| drug ineffective | 543 | 1.4 | 1.3 | 65 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.